Compare Neurocrine Biosciences Inc (NBIX) vs Oracle Corporation (ORCL) Price & Performance

Neurocrine Biosciences IncTrade

Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Oracle Corporation — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Oracle Corporation trades at $127.91 (market cap $349.63B). The key difference: Oracle Corporation is far larger — about 20.1× Neurocrine Biosciences Inc's market cap, and Oracle Corporation pays a 1.65% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

	NBIX	ORCL
Market Cap	$17.40B	$349.63B
Sector	Health	Technology
52-Week High	$180.55	$328.33
52-Week Low	$123.10	$121.37
Enterprise Value	$16.49B	$478.88B
Dividend Yield	—	1.65%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

No Aura AI signal available yet.

Oracle Corporation

Oracle (ORCL) trades at $126.48, up 1.78% today, with a strong fundamental backdrop including revenue growth to $57.40B in 2025 and a net income margin of 25.37%. Recent quarters have consistently beaten EPS estimates, and analyst consensus is bullish with a $253.30 price target. Technicals show a bearish overall signal but with bullish oscillators, and the stock faces support near $125.

The outlook is positive given Oracle's AI infrastructure expansion and earnings momentum, but risks include high debt levels and competitive pressures. The stock offers growth potential if execution continues, yet investors should weigh valuation multiples against sector peers.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NBIX

Neurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer to lead growth strategy.PRNewsWire · 7 hours agoBullish View details →

ORCL

Oracle shares hit key support and show oversold signs, hinting at a possible rebound soon.FXEmpire · 6 hours agoBullish Big tech's hidden debt hits $1.65T, raising investor risk amid AI investment surge.Finbold · 18 hours agoBearish Oracle shifts to AI hyperscale, faces credit downgrade but shows strong growth potential.Stuart Mooney · 1 day agoNeutral View details →

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.